Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, ...

This was the stock's fifth consecutive day of losses.

(KTLA) – A 44-year-old teacher with the Irvine Unified School District was arrested over the weekend for an alleged sexually ...

The lead actor of a new action-packed film is sharing his preparation journey for his role as a war veteran while working ...

A slow start proved costly for the Mount Gilead girls’ basketball Tuesday night when visiting Delaware Christian edged them by a 42-36 margin.

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...